Clinical trials of immunotherapy targeting survivin have been performed in multiple cancer types, including melanoma, ovarian cancer, glioblastoma and prostate cancer [7,36,37,38,39,40,41,42]. The gene discussed is BIRC5; the disease is prostate cancer.